APHEXDA Drug Patent Profile
✉ Email this page to a colleague
When do Aphexda patents expire, and what generic alternatives are available?
Aphexda is a drug marketed by Biolinerx Ltd and is included in one NDA.
The generic ingredient in APHEXDA is motixafortide acetate. One supplier is listed for this compound. Additional details are available on the motixafortide acetate profile page.
Summary for APHEXDA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| What excipients (inactive ingredients) are in APHEXDA? | APHEXDA excipients list |
| DailyMed Link: | APHEXDA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for APHEXDA
Generic Entry Date for APHEXDA*:
Constraining patent/regulatory exclusivity:
TO MOBILIZE HEMATOPOIETIC STEM CELLS TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA NDA:
Dosage:
POWDER;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for APHEXDA
APHEXDA is protected by zero US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of APHEXDA is ⤷ Try a Trial.
This potential generic entry date is based on TO MOBILIZE HEMATOPOIETIC STEM CELLS TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
FDA Regulatory Exclusivity protecting APHEXDA
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial
TO MOBILIZE HEMATOPOIETIC STEM CELLS TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biolinerx Ltd | APHEXDA | motixafortide acetate | POWDER;SUBCUTANEOUS | 217159-001 | Sep 8, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Biolinerx Ltd | APHEXDA | motixafortide acetate | POWDER;SUBCUTANEOUS | 217159-001 | Sep 8, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
